IXICO plc announced that an existing client has contracted IXICO to provide imaging services for the extension study of their Huntington's disease ('HD') Ph2b trial. This is a new study protocol and results in a new work order worth just under £2 million which IXICO expects to deliver over the next 4 years.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.625 GBX | 0.00% | -1.43% | -31.00% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-31.00% | 5.19M | |
+1.51% | 42.75B | |
+8.57% | 41.34B | |
+49.22% | 41.61B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- IXI Stock
- News IXICO plc
- IXICO plc Announces Contract Win in Huntington's Disease